http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-993453-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4acae202b6a15394281949545e70d2f6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0075 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10 |
| filingDate | 1964-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1965-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-993453-A |
| titleOfInvention | New derivatives of heparin and processes for their preparation |
| abstract | The invention comprises O-methyl-N-methyl heparinamides and non-toxic salts thereof. The compounds may be prepared by reaction of a long-chain quaternary ammonium salt of an N-methyl heparinamide (Specification 973,893) with a methyl halide in presence of silver oxide, to form an O-methyl-N-methyl heparinamide in which the sulphonic acid groups are unesterified. The reaction may be carried out in an inert organic solvent, e.g. tetrahydrofuran, at below room temperature. The amounts of amidation and of methylation of the O-methyl-N-methyl heparinamide are preferably 60-100%. The compound may be converted to an alkali metal salt by reaction in aqueous medium with an alkali metal carboxylate e,g. sodium acetate. The salt may be isolated by precipitation in presence of an alkanol. The O-methyl-N-methyl heparinamides are used, in conjunction with carriers, as pharmaceutical compositions having antilepaemic activity (see Divisions A5).ALSO:Pharmaceutical compositions having antilipaemic activity contain an O-methyl-N-methyheparinamide (Division C3) in association with a carrier. The compositions may be administered as a tablet or coated tablet, when the carrier is a tablet base and/or diluting agent; perlingually, in the form of a glossette; rectally, in the form of a suppository, when the carrier is a suppository base, and subcutaneously by intramuscular or intravenous injection, when the carrier may be a sterile aqueous or non-aqueous injection solution or suspension medium. The injection may be presented in unit dose ampoules or multi-dose containers and may contain an antioxidant, a buffer, a bacteriostat and/or a solute which renders the medium isotonic with the blood. Alternatively, the injection solution or suspension may be formed extemporaneously, immediately prior to administration, from a sterile tablet or powder containing the specified ingredients and binding agents and/or lubricants. |
| priorityDate | 1963-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.